Oaktree Acquisition Corp. III Life Sciences (OACC)
OACC 8-K filings, explained
Every material Form 8-K Oaktree Acquisition Corp. III Life Sciences has filed with the SEC since October 29, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Oaktree Acquisition Corp. III Life Sciences moved its extraordinary general meeting, which was set for October 16, 2026, to October 23, 2026, to allow more time to solicit and collect proxy votes on a proposal to extend its deadline for completing an initial business combination. The record date of September 22, 2026 is unchanged, and previously submitted proxies remain valid.
Extraordinary general meeting moved from October 16, 2026 to October 23, 2026, at 10:00 a.m. Eastern Time
Shareholders wishing to attend in person must reserve attendance with the CEO by October 21, 2026
Record date remains September 22, 2026; existing proxies stay valid unless revoked
Redemption withdrawal requests may continue to be made until the rescheduled meeting
Oaktree Acquisition Corp. III Life Sciences disclosed preliminary results of its shareholder redemption window ahead of an extension meeting. Holders tendered 13,326,977 Class A ordinary shares for redemption before the October 14, 2026 deadline. After the redemptions and a planned conversion of sponsor-held Class B shares, the company expects 11,254,791 Class A and 1,000 Class B ordinary shares to remain outstanding, which matters to shareholders because it sets the share count ahead of the proposed deadline extension.
Redemption deadline was 5:00 p.m. Eastern Time on October 14, 2026.
13,326,977 Class A ordinary shares were tendered for redemption before the deadline.
Sponsor intends to convert 4,798,758 Class B ordinary shares into Class A ordinary shares before the extension takes effect.
Shareholders meeting to vote on the extension is scheduled for October 16, 2026.
Chief Financial Officer Thomas Sweeney resigned effective October 29, 2025, to pursue other professional opportunities, according to the filing, and the filing states the resignation was not due to any disagreement with the board or management. The board appointed George A. Martinez, a Senior Vice President in Oaktree's finance organization, as CFO effective immediately, and he will not receive compensation from the company for the role.
Thomas Sweeney resigned as Chief Financial Officer effective October 29, 2025, citing other professional opportunities
George A. Martinez appointed Chief Financial Officer and principal accounting and financial officer effective October 29, 2025
Martinez previously was an Audit Senior Manager at Ernst & Young from 2013 to 2024 and joined Oaktree in 2024
Martinez will not be compensated by the company for the CFO role and has no employment agreement with it
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Oaktree Acquisition Corp. III Life Sciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →